Viridian Therapeutics Inc (NASDAQ: VRDN) kicked off on Tuesday, down -8.31% from the previous trading day, before settling in for the closing price of $13.12. Over the past 52 weeks, VRDN has traded in a range of $9.90-$27.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -4.11% over the last five years. While this was happening, its average annual earnings per share was recorded -8.03%. With a float of $73.60 million, this company’s outstanding shares have now reached $80.99 million.
The firm has a total of 143 workers. Let’s measure their productivity. In terms of profitability, gross margin is -1972.52%, operating margin of -99018.54%, and the pretax margin is -89387.09%.
Viridian Therapeutics Inc (VRDN) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc is 9.79%, while institutional ownership is 105.07%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -8.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.18% during the next five years compared to 31.28% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Take a look at Viridian Therapeutics Inc’s (VRDN) current performance indicators. Last quarter, stock had a quick ratio of 15.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3271.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.77, a number that is poised to hit -1.02 in the next quarter and is forecasted to reach -3.85 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Analysing the last 5-days average volume posted by the [Viridian Therapeutics Inc, VRDN], we can find that recorded value of 0.8 million was lower than the volume posted last year of 1.01 million. As of the previous 9 days, the stock’s Stochastic %D was 18.25%. Additionally, its Average True Range was 0.87.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 15.49%, which indicates a significant increase from 1.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.95% in the past 14 days, which was lower than the 65.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.07, while its 200-day Moving Average is $18.03. Now, the first resistance to watch is $12.69. This is followed by the second major resistance level at $13.36. The third major resistance level sits at $13.70. If the price goes on to break the first support level at $11.68, it is likely to go to the next support level at $11.34. Now, if the price goes above the second support level, the third support stands at $10.67.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
The company with the Market Capitalisation of 981.52 million has total of 81,590K Shares Outstanding. Its annual sales at the moment are 300 K in contrast with the sum of -269,950 K annual income. Company’s last quarter sales were recorded 70 K and last quarter income was -79,730 K.
